It has been stated that cancer patients in England are better off because there are five times more likelihood of terminally ill cancer patients receiving life-prolonging drugs as compared in Wales.
In England there are about 24 new cancer treatments that are being prescribed but in Wales this is absent, the Rarer Cancers Foundation said.
As of now the NHS does not approve of any cancer drug funds but England’s case will pressurize the Welsh Government to follow England’s lead and this will improve people getting access to better treatments.
The yearly cost of making treatment accessible to people is being estimated at £3.3m, according to the foundation, which receives financial support from pharmaceutical companies.
Andrew Wilson, chief executive of the Rarer Cancers Foundation, said, “Wales is in danger of becoming the sick man of Britain when it comes to cancer services. This is a devastating divide. A cancer drug does not become any less effective simply because it is prescribed on the other side of a border.”
He added that every cancer patient has the same need and with the same urgency.